gebhart/patrepeval huggingface dataset:
Resistance to H-2-restricted but not to allo-H2-specific graft and cytotoxic T lymphocyte responses in lymphoma mutant. (1990)

The lymphoma mutant RMA-S escaped graft rejection after transplantation over a minor histocompatibility barrier, whereas it was rejected in H-2 allogeneic mice. The parental control line was rejected in both situations. The mutant, which had been selected against MHC class I molecules retained 5 to 10% of the wild-type H-2Db, Kb, and beta 2-microglobulin expression on the cell surface. It remained sensitive to allo-H-2b CTL in vitro, but was completely resistant to minor histocompatibility antigen-specific, H-2b-restricted CTL. It was equally resistant to other H-2b-restricted responses against internally derived Ag, such as tumor-specific CTL or a CTL clone specific for the influenza virus nucleoprotein. The results indicate a target cell defect that selectively abolishes the sensitivity to H-2-restricted CTL directed against internally processed Ag. This appears sufficient to shift the transplantation response over a minor histocompatibility Ag barrier from rejection to acceptance. There are two possible explanations for the results: 1) a block in the MHC class I-directed pathway for internal Ag processing, and 2) subthreshold H-2/Ag ligand density in relation to triggering requirements of restricted CTL. Regardless of the type of defect, the results demonstrate a difference between allo-H-2-specific and H-2-restricted CTL recognition at the level of the target cell.
Regulated expression of a complete human beta-globin gene encoded by a transmissible retrovirus vector. (1987)

We introduced a human beta-globin gene into murine erythroleukemia (MEL) cells by infection with recombinant retroviruses containing the complete genomic globin sequence. The beta-globin gene was correctly regulated during differentiation, steady-state mRNA levels being induced 5- to 30-fold after treatment of the cells with the chemical inducer dimethyl sulfoxide. Studies using vectors which yield integrated proviruses lacking transcriptional enhancer sequences indicated that neither retroviral transcription nor the retroviral enhancer sequences themselves had any obvious effect on expression of the globin gene. Viral RNA expression also appeared inducible, being considerably depressed in uninduced MEL cells but approaching normal wild-type levels after dimethyl sulfoxide treatment. We provide data which suggest that the control point for both repression and subsequent activation of virus expression in MEL cells lies in the viral enhancer element.
Macular pigment and age related macular degeneration (1999)

The yellow coloration of the macula lutea is attributable to the presence of macular pigment in the axons of its photoreceptors.1 In the 1980s several investigators demonstrated that macular pigment consists of the xanthophyll isomers, lutein and zeaxanthin.2 3 Although the role of the macular pigment remains uncertain, several functions have been hypothesised and these include reduction of the effects of light scatter and chromatic aberration on visual performance,4 5 limitation of the damaging photo-oxidative effects of blue light through its absorption,6-8 and protection against the adverse effects of photochemical reactions because of the antioxidant properties of the carotenoids.9 10 

Age related macular degeneration (AMD) is the leading cause of visual loss in people over the age of 65 years in the Western world.11 Although the aetiopathogenesis of AMD remains a matter of debate, there is a growing body of evidence to indicate that oxidative damage plays a role.12-14 Consequently, the possibility that the absorption characteristics and antioxidant properties of macular pigment confer protection against AMD has been postulated.10 15 A proved protective effect of macular pigment may be of therapeutic value, as it has recently been reported that human macular pigment can be augmented with dietary modification.16 

In this article we review the current literature germane to macular pigment and AMD, and examine the evidence that retinal carotenoids are protective against AMD.

The absorption of blue light by the macular pigment was first described in 1866 by Max Schultze who concluded: “Therefore, under an otherwise equal organisation, a retina without a yellow spot would see more blue light than one with such a spot”.17 He believed that absorption of the “most refractable violet” reduced chromatic aberration, but also hypothesised that macular pigment might provide some protection against the hazards …
THE ROLE OF THE IKAROS GENE IN LYMPHOCYTE DEVELOPMENT AND HOMEOSTASIS (1997)

The Ikaros gene, which encodes a family of hemopoietic-specific zinc finger proteins, is described as a central regulator of lymphocyte differentiation. During fetal development, it is required at the earliest stage of T cell and B cell specification. In the adult, however, lymphoid lineages rely on Ikaros at distinct phases of their development. Its activity is essential for the generation of B cell but not of T cell precursors, although the differentiation of the latter is not normal. A significant increase in CD4 thymocytes and their immediate precursors is detected, and because these cells lack markers that correlate with positive selection, a deregulation in their maturation process is suggested. Furthermore, Ikaros-null thymocytes hyperproliferate in response to T cell receptor (TCR) signaling; within days after their appearance in the thymus, clonally expanding populations are detected. Deregulated TCR-mediated responses and the fast kinetics of tumor development in these mutant thymocytes implicate Ikaros as a central tumor suppressor gene for the T cell lineage. In addition, lack of natural killer cells and selective defects in gamma delta T cells and dendritic antigen-presenting cells point to Ikaros as an essential factor for the establishment of early branchpoints of the T cell pathway. The dominant interference activity of Ikaros isoforms unable to bind DNA and their effects in lymphocyte development suggest that Ikaros works in concert with other factors. The role of Aiolos, a lymphoid-restricted and structurally related gene, in lymphoid differentiation is discussed. A model is proposed that defines Ikaros as the backbone of a complex regulatory protein network that controls cell fate decisions and regulates homeostasis in the hemo-lymphoid system. Changes in this regulatory network may reflect differentiation and proliferation adjustments made in hemo-lymphoid progenitors and precursors as they give rise to the cells of our immune system.
Tat cell‐penetrating peptide has the characteristics of a poly(proline) II helix in aqueous solution and in SDS micelles (2004)

Tat cell-penetrating peptide (GRKKRRQRRRPPQG) is able to translocate and carry molecules across cell membranes. Using CD spectroscopy the conformation of this synthetic peptide was studied in aqueous and membrane-mimicking, micellar SDS solutions at different temperatures. The CD spectrum of the Tat cell-penetrating peptide in SDS micellar solution was virtually unchanged from that in aqueous solution, and at low temperature it was close to that of a poly(proline) II helix.
High dose rate brachytherapy : a textbook (1994)

Part I: Introduction, Physics and Radiobiology: Evolution and General Principles of High Dose Rate Brachytherapy Radiobiology Design and Implementation of a Program for High Dose Rate Brachytherapy High Dose Rate Remote Afterloading Equipment Calibration Principles and Techniques Treatment Planning and Optimization Quality Assurance for High Dose Rate Brachytherapy Part II: Clinical Body Sites: High Dose Rate Brachytherapy in the Treatment of Malignant Gliomas High Dose Rate Brachytherapy for Cancer of the Head and Neck High Dose Rate Brachytherapy for Carcinoma of the Esophagus High Dose Rate Brachytherapy for Lung Cancer High Dose Rate Brachytherapy for Breast Cancer Remote Afterloading High Dose Rate Brachytherapy for Carcinoma of the Bile Duct Interstitial High Dose Rate Irradiation for Hepatic Tumors The Role of High Dose Rate Brachytherapy in Rectal Cancer High Dose Rate Brachytherapy of the Prostate High Dose Rate Brachytherapy for Carcinoma of the Cervix The Role of High Dose Rate Brachytherapy in Carcinoma of the Endometrium The Role of High Dose Rate Brachytherapy in the Management of Adult Soft Tissue Sarcomas High Dose Rate Remote Brachytherapy in the Treatment of Pediatric Tumors Part III: Special Topics: High Dose Rate Brachytherapy Nursing Intraoperative High Dose Rate Remote Brachytherapy The future of High Dose Rate Brachytherapy
Human PTH-(7-84) Inhibits Bone Resorptionin VitroVia Actions Independent of the Type 1 PTH/PTHrP Receptor (2002)

The linear sequence of intact mammalian PTH consists of 84 amino acids, of which only the most amino(N)-terminal portion, i.e. PTH-(1-34), is required for the classical actions of the hormone on mineral ion homeostasis mediated by the type 1 PTH/PTHrP receptor (PTH1R). Like the N-terminus, the carboxyl (C)-terminal sequence of PTH is highly conserved among species, and various circulating PTH C-fragments are generated by peripheral metabolism of intact PTH or are directly secreted, in a calcium-dependent manner, by the parathyroid glands. Certain synthetic PTH C-fragments exert actions on bone and cartilage cells that are not shared by PTH-(1-34), and specific binding of PTH C-peptides has been demonstrated in bone cells in which PTH1R expression was eliminated by gene targeting. The peptide human (h) PTH-(7-84) recently was shown to inhibit the calcemic actions of hPTH-(1-34) or hPTH-(1-84) in parathyroidectomized animals. To determine whether this anticalcemic effect of hPTH-(7-84) in vivo might result from direct actions on bone, we studied its effects on both resorption of intact bone in vitro and formation of osteoclasts in primary cultures of murine bone marrow. Human (h) PTH-(7-84) (300 nM) reduced basal 72-h release of preincorporated (45)Ca from neonatal mouse calvariae by 50% (9.6 +/- 1.9% vs. 17.8 +/- 5.7%; P < 0.001) and similarly inhibited resorption induced by hPTH-(1-84), hPTH-(1-34), 1,25-dihydroxyvitamin D(3) (VitD), PGE(2), or IL-11. In 12-d murine marrow cultures, both hPTH-(7-84) (300 nM) and hPTH-(39-84) (3000 nM) lowered VitD-dependent formation of osteoclast-like cells by 70%. On the contrary, these actions of hPTH-(7-84) were not observed with the PTH1R antagonists hPTH-(3-34)NH(2) and [L(11),D-W(12),W(23),Y(36)]hPTHrP-(7-36)NH(2), which, unlike hPTH-(7-84), did inhibit PTH1R-dependent cAMP accumulation in ROS 17/2.8 cells. We conclude that hPTH-(7-84), acting via receptors distinct from the PTH1R and presumably specific for PTH C-fragments, exerts a direct antiresorptive effect on bone that may be partly due to impaired osteoclast differentiation.
4-Substituted Resorcinols (Sulfite Alternatives) as Slow-Binding Inhibitors of Tyrosinase Catecholase Activity (1997)

A kinetic study of the inhibition of mushroom tyrosinase catecholase activity by 4-substituted resorcinols has been made. The results obtained show that 4-substituted resorcinols inhibit tyrosinase in a nonclassical manner and that the inhibition is characterized by a long transient phase. Progress curves of enzymatic reaction in the presence of inhibitor show a progressive decrease in initial velocity followed by a constant steady-state rate. Both the initial and the constant rates decreased with increasing concentrations of inhibitor. Kinetic data obtained correspond to those for a postulated mechanism involving rapid formation of an enzyme−inhibitor complex that subsequently undergoes a relatively slow reversible reaction. The kinetic parameters characterizing this time-dependent inhibition were evaluated by means of nonlinear regression of the product accumulation curves. Keywords: Tyrosinase; 4-hexylresorcinol; slow-binding inhibitors
Mitochondria-Targeted Peptide Accelerates ATP Recovery and Reduces Ischemic Kidney Injury (2011)

The burst of reactive oxygen species (ROS) during reperfusion of ischemic tissues can trigger the opening of the mitochondrial permeability transition (MPT) pore, resulting in mitochondrial depolarization, decreased ATP synthesis, and increased ROS production. Rapid recovery of ATP upon reperfusion is essential for survival of tubular cells, and inhibition of oxidative damage can limit inflammation. SS-31 is a mitochondria-targeted tetrapeptide that can scavenge mitochondrial ROS and inhibit MPT, suggesting that it may protect against ischemic renal injury. Here, in a rat model of ischemia-reperfusion (IR) injury, treatment with SS-31 protected mitochondrial structure and respiration during early reperfusion, accelerated recovery of ATP, reduced apoptosis and necrosis of tubular cells, and abrogated tubular dysfunction. In addition, SS-31 reduced medullary vascular congestion, decreased IR-mediated oxidative stress and the inflammatory response, and accelerated the proliferation of surviving tubular cells as early as 1 day after reperfusion. In summary, these results support MPT as an upstream target for pharmacologic intervention in IR injury and support early protection of mitochondrial function as a therapeutic maneuver to prevent tubular apoptosis and necrosis, reduce oxidative stress, and reduce inflammation. SS-31 holds promise for the prevention and treatment of acute kidney injury.
Solution structure of an ATP-binding RNA aptamer reveals a novel fold. (1996)

In vitro selection has been used to isolate several RNA aptamers that bind specifically to biological cofactors. A well-characterized example in the ATP-binding RNA aptamer family, which contains a conserved 11-base loop opposite a bulged G and flanked by regions of double-stranded RNA. The nucleotides in the consensus sequence provide a binding pocket for ATP (or AMP), which binds with a Kd in the micromolar range. Here we present the three-dimensional solution structure of a 36-nucleotide ATP-binding RNA aptamer complexed with AMP, determined from NMR-derived distance and dihedral angle restraints. The conserved loop and bulged G form a novel compact, folded structure around the AMP. The backbone tracing of the loop nucleotides can be described by a Greek zeta (zeta). Consecutive loop nucleotides G, A, A form a U-turn at the bottom of the zeta, and interact with the AMP to form a structure similar to a GNRA tetraloop, with AMP standing in for the final A. Two asymmetric G. G base pairs close the stems flanking the internal loop. Mutated aptamers support the existence of the tertiary interactions within the consensus nucleotides and with the AMP found in the calculated structures.
Structure of the reaction product of o-benzoyl-benzoic acid with ethylenediamine (1967)

ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTStructure of the reaction product of o-benzoyl-benzoic acid with ethylenediamineWerner Metlesics, T. Anton, and Leo H. SternbachCite this: J. Org. Chem. 1967, 32, 7, 2185–2187Publication Date (Print):July 1, 1967Publication History Published online1 May 2002Published inissue 1 July 1967https://pubs.acs.org/doi/10.1021/jo01282a023https://doi.org/10.1021/jo01282a023research-articleACS PublicationsRequest reuse permissionsArticle Views139Altmetric-Citations16LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose Get e-Alerts
Somatic gene transfer in the development of an animal model for primary hyperparathyroidism. (1992)

The overproduction of hormones is associated with a variety of endocrinological disorders. We have used somatic cell gene transfer of human PTH (hPTH) to develop an animal model of hypercalcemia and osteoclastic skeletal resorption. Recombinant retroviruses were used to transduce a functional hPTH gene into cultured rat fibroblasts. The recombinant-derived preproparathyroid hormone peptide was appropriately processed in this ectopic cell, and intact hPTH (1-84) was secreted at a high level (2-5 ng/10(6) cells/24 h). Transplantation of the PTH-secreting cells into syngeneic rat recipients was associated with the development of hypercalcemia mediated by increasing serum concentrations of hPTH. Thyroparathyroidectomy in these hypercalcemic rats producing hPTH did not result in hypocalcemia and tetany, which was observed in control animals undergoing thyroparathyroidectomy. Chronic overproduction of hPTH (60 days) was associated with severe hypercalcemia, metastatic calcification, and histological changes of osteoclastic resorption of bone. This animal model will be useful in studying the pathophysiology of severe hyperparathyroidism in humans and should help in the evaluation of new medical therapies for hypercalcemia.
Efficacy of desmopressin in treatment of nocturia in elderly men. (2011)

Oral administration of desmopressin is an effective and well-tolerated treatment for nocturia in elderly men.
On the correctness of transactional memory (2008)

Transactional memory (TM) is perceived as an appealing alternative to critical sections for general purpose concurrent programming. Despite the large amount of recent work on TM implementations, however, very little effort has been devoted to precisely defining what guarantees these implementations should provide. A formal description of such guarantees is necessary in order to check the correctness of TM systems, as well as to establish TM optimality results and inherent trade-offs.
Antisense Antivirals (1991)

The antiviral use of antisense oligonucleotides is described with particular reference to our own work on the inhibition of HIV-1. Subjects include the design, metabolism, and modification of these agents and the possible future use of ribozymes.
Octreotide in Dumping and Short Bowel Syndromes (1993)

Octreotide inhibits intestinal motility and reduces gastrointestinal secretions. These actions have led to its evaluation in two postsurgical conditions: dumping syndrome and short bowel syndrome. Octreotide substantially reduces symptoms of early and late dumping and prevents the associated phenomena including the increase in packed cell volume considered to be indicative of reduced plasma volume. Its therapeutic benefit probably relates both to slowing of gastric emptying and small bowel transit and inhibition of the release of putative mediators (peptide hormones) of the vasomotor symptoms. Octreotide also reduces intestinal efflux in some patients with the short bowel syndrome. This can lead to a reduction in the volume of intravenous fluid requirements but does not allow an intravenous fluid-dependent patient to change back to an oral regimen. The major mechanism of octreotide's therapeutic effect in this situation may be its ability to reduce endogenous gastric acid secretion.
Diameter‐Controlled Synthesis of Silicon Nanowires Using Nanoporous Alumina Membranes (2005)

The use of nanoporous alumina membranes to control the diameter of silicon nanowires synthesized by vapor–liquid–solid growth is demonstrated. An increase in nanowire diameter was observed when the nanowires grew out from the top surface of the membrane (see Figure). The diameter increase was attributed to a change in the shape of the Au–Si liquid alloy when the nanowires emerged from the membrane surface.
Generic and Scalable Framework for Automated Time-series Anomaly Detection (2015)

This paper introduces a generic and scalable framework for automated anomaly detection on large scale time-series data. Early detection of anomalies plays a key role in maintaining consistency of person's data and protects corporations against malicious attackers. Current state of the art anomaly detection approaches suffer from scalability, use-case restrictions, difficulty of use and a large number of false positives. Our system at Yahoo, EGADS, uses a collection of anomaly detection and forecasting models with an anomaly filtering layer for accurate and scalable anomaly detection on time-series. We compare our approach against other anomaly detection systems on real and synthetic data with varying time-series characteristics. We found that our framework allows for 50-60% improvement in precision and recall for a variety of use-cases. Both the data and the framework are being open-sourced. The open-sourcing of the data, in particular, represents the first of its kind effort to establish the standard benchmark for anomaly detection.
[Applications of antisense oligonucleotides in oncology]. (1994)

The development of biotechnologies offers considerable potential for new therapeutical approaches, targetting nucleic acids as information bearing molecules responsible for various pathologies. Gene therapy has, up to now, mainly aimed at compensating deficiencies of gene expression, through complex molecular and cellular constructions. Recently, an increasing interest has focused on short nucleotidic sequences (thus relatively easy to synthetize), or oligonucleotides, which could be able to specifically block the expression of mutated or overexpressed genes. When the target of these oligonucleotides is the mRNA of such genes, the strategy is called "antisense". This strategy has already led to a number of successful results in experimental models in vitro. Much more rare are actual effects in animal models and clinical trials are just being sketched. A review on the current state of the art will enlighten the physiological potential of these new molecules but also underline the still numerous issues before controlling therapeutical applications.
Differentiation of Listeria monocytogenes, Listeria innocua, Listeria ivanovii, and Listeria seeligeri by pulsed-field gel electrophoresis (1992)

Clamped homogeneous electric field analysis of Listeria DNA with ApaI, AscI, SmaI, or NotI revealed species- and serotype-specific differences in genomic fingerprints. Clamped homogeneous electric field analysis may prove useful, therefore, in epidemiologic studies. Also, the summation of individually sized AscI fragments of genomic DNA from L. monocytogenes serotype 4b 101M and Scott A indicated genome lengths of 2,925 and 3,046 kb, respectively.